TY  - JOUR
AU  - Stahl, Maximilian
AU  - DeVeaux, Michelle
AU  - Montesinos, Pau
AU  - Itzykson, Raphaël
AU  - Ritchie, Ellen K
AU  - Sekeres, Mikkael A
AU  - Barnard, John
AU  - Podoltsev, Nikolai A
AU  - Brunner, Andrew
AU  - Komrokji, Rami S
AU  - Bhatt, Vijaya R
AU  - Al-Kali, Aref
AU  - Cluzeau, Thomas
AU  - Santini, Valeria
AU  - Roboz, Gail J
AU  - Fenaux, Pierre
AU  - Litzow, Mark
AU  - Fathi, Amir T
AU  - Perreault, Sarah
AU  - Kim, Tae Kon
AU  - Prebet, Thomas
AU  - Vey, Norbert
AU  - Verma, Vivek
AU  - Germing, Ulrich
AU  - Bergua, Juan
AU  - Serrano, Josefina
AU  - Gore, Steven D
AU  - Zeidan, Amer M
PY  - 2018
DO  - 10.1080/10428194.2018.1468893
UR  - http://hdl.handle.net/10668/12666
T2  - Leukemia & lymphoma
LA  - en
KW  - Adolescent
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Hematopoietic Stem Cell Transplantation
KW  - Humans
KW  - Leukemia, Myeloid, Acute
KW  - Male
KW  - Middle Aged
KW  - Neoplasm Recurrence, Local
KW  - Prognosis
KW  - Retrospective Studies
KW  - Risk Assessment
KW  - Risk Factors
KW  - Survival Analysis
KW  - Transplantation, Homologous
KW  - Treatment Outcome
KW  - Young Adult
TI  - Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia.
TY  - research article
VL  - 60
ER  -